Hye Ryun Kim
0000-0002-1842-9070
Yonsei Cancer Center
2 papers found
Refreshing results…
A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
Missing publications? Search for publications with a matching author name.